Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Yoichi Matsuo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9654-6080; OpenAlex author ID A5102713327. Sources: OpenAlex.

Their work

Papers
23 (first author 15, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 23

  1. Interleukin-1 receptor type 1 in pancreatic cancer progression and metastasis: a review. First author DOI 10.1007/s10147-026-03000-7↗
  2. Kaempferol Inhibits MMP-1-Mediated Migration and Invasion in Gemcitabine-Resistant Pancreatic Cancer Cells. First author DOI 10.3390/nu18030380↗
  3. The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancre… First author DOI 10.3390/nu17162641↗
  4. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. Co-author DOI 10.1002/cam4.70124↗
  5. Expression of ZKSCAN3 protein suppresses proliferation, migration, and invasion of pancreatic cancer through autophagy. First author DOI 10.1111/cas.16173↗
  6. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in… First author DOI 10.3390/nu16050705↗
  7. Concomitant Pancreatic Ductal Adenocarcinoma and Type 1 Autoimmune Pancreatitis: A Potential Issue in the Diagnosis of Carcinoma by Endoscopic Ultrasound-guide… Co-author DOI 10.2169/internalmedicine.0075-22↗
  8. Clinical Outcomes of Intraoperative Radiotherapy, Postoperative Radiotherapy, and Definitive Radiotherapy for Non-metastatic Pancreatic Cancer. Co-author DOI 10.2739/kurumemedj.ms674002↗
  9. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer. First author DOI 10.3892/or.2023.8601↗
  10. Girdin regulates both migration and angiogenesis in pancreatic cancer cell lines. First author DOI 10.3892/or.2023.8606↗
  11. 10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines. First author DOI 10.3892/or.2022.8259↗
  12. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. First author DOI 10.3892/or.2022.8279↗
  13. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer. Co-author DOI 10.1093/carcin/bgab017↗
  14. Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreat… First author DOI 10.3892/or.2021.8006↗
  15. Metachronous Pancreatic Ductal Adenocarcinoma with Adjacent Serous Cystadenoma that Was Preoperatively Diagnosed by EUS-FNA: A Case Report and Review of the Li… Co-author DOI 10.2169/internalmedicine.3912-19↗
  16. Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer. First author DOI 10.3892/or.2019.7105↗
  17. [A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy]. First author PMID 32156996↗
  18. Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. First author DOI 10.1111/cas.13441↗
  19. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. First author DOI 10.1186/s12885-016-2340-z↗
  20. Zerumbone inhibits angiogenesis by blocking NF-κB activity in pancreatic cancer. First author DOI 10.1097/mpa.0000000000000039↗
  21. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2013.08.006↗
  22. Cytokine network: new targeted therapy for pancreatic cancer. Co-author DOI 10.2174/13816128112092416↗
  23. Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. Co-author DOI 10.1002/jcp.22421↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuji Takiguchi · 13 shared papers, 2018–2026 · strength 2.01
  2. Kenta Saito · 14 shared papers, 2016–2026 · strength 1.98
  3. Tomokatsu Kato · 10 shared papers, 2021–2026 · strength 1.70
  4. Hiromichi Murase · 9 shared papers, 2022–2026 · strength 1.65
  5. Hiroki Takahashi · 14 shared papers, 2013–2025 · strength 1.63
  6. Keisuke Nonoyama · 7 shared papers, 2023–2026 · strength 1.38
  7. Yuki Denda · 7 shared papers, 2023–2026 · strength 1.38
  8. Mamoru Morimoto · 11 shared papers, 2016–2024 · strength 1.34
  9. Hiroyuki Imafuji · 10 shared papers, 2018–2024 · strength 1.29
  10. Yuichi Hayashi · 7 shared papers, 2019–2023 · strength 0.85
  11. Saburo Sugita · 4 shared papers, 2024–2026 · strength 0.80
  12. Yuki Eguchi · 4 shared papers, 2024–2026 · strength 0.80
  13. Kan Omi · 6 shared papers, 2019–2023 · strength 0.70
  14. Goro Ueda · 6 shared papers, 2019–2023 · strength 0.70
  15. Akihisa Kato · 4 shared papers, 2020–2024 · strength 0.57
  16. Satoru Takahashi · 4 shared papers, 2020–2024 · strength 0.57
  17. Kenta Kachi · 3 shared papers, 2020–2023 · strength 0.38
  18. Shingo Inaguma · 2 shared papers, 2021–2024 · strength 0.32
  19. Hiroyuki Kato · 2 shared papers, 2021–2024 · strength 0.32
  20. Itaru Naitoh · 2 shared papers, 2020–2023 · strength 0.25
  21. Hiromi Kataoka · 2 shared papers, 2020–2023 · strength 0.25
  22. Yasuki Hori · 2 shared papers, 2020–2023 · strength 0.25
  23. Michihiro Yoshida · 2 shared papers, 2020–2023 · strength 0.25
  24. Makoto Sano · 1 shared paper, 2024 · strength 0.20
  25. Hideaki Ijichi · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.